Literature DB >> 16707417

Regulatory T cells and toll-like receptors in cancer therapy.

Rong-Fu Wang1.   

Abstract

T regulatory (Treg) cells that suppress immune responses may limit the efficiency of cancer immunotherapy. Recent findings indicate that Toll-like receptors (TLR) directly regulate the suppressive activity of Treg cells. Linking TLR signaling to the functional control of Treg cells may offer new opportunities to improve the outcome of cancer immunotherapy by coadminstration of certain TLR ligands.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16707417     DOI： 10.1158/0008-5472.CAN-05-4676

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  7 in total

1.  Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2010-04-07

Review 2.  Toll-Like Receptors in the Pathogenesis of Autoimmune Diseases.

Authors:  Akbar Mohammad Hosseini; Jafar Majidi; Behzad Baradaran; Mehdi Yousefi
Journal:  Adv Pharm Bull       Date:  2015-12-31

Review 3.  Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.

Authors:  Swethajit Biswas; Tim Eisen
Journal:  Nat Rev Clin Oncol       Date:  2009-06-23       Impact factor: 66.675

Review 4.  Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells.

Authors:  Guangwei Liu; Yong Zhao
Journal:  Immunology       Date:  2007-10       Impact factor: 7.397

5.  The role of SMAC mimetics in regulation of tumor cell death and immunity.

Authors:  Perpetua U Emeagi; Kris Thielemans; Karine Breckpot
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

6.  The TLR7 agonist induces tumor regression both by promoting CD4⁺T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells.

Authors:  Chenchen Wang; Quan Zhou; Xiaofeng Wang; Xiongyan Wu; Xuehua Chen; Jianfang Li; Zhenggang Zhu; Bingya Liu; Liping Su
Journal:  Oncotarget       Date:  2015-01-30

Review 7.  Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Yoshihisa Namiki; Kazuki Takakura; Kan Uchiyama; Mikio Kajihara; Seiji Arihiro; Hiroo Imazu; Hiroshi Arakawa; Shin Kan; Hideo Komita; Yuko Kamata; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.